Prime Medicine Statistics
Total Valuation
Prime Medicine has a market cap or net worth of $569.95 million. The enterprise value is $546.85 million.
Important Dates
The next estimated earnings date is Monday, August 4, 2025, after market close.
| Earnings Date | Aug 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Prime Medicine has 131.02 million shares outstanding. The number of shares has increased by 32.05% in one year.
| Current Share Class | 131.02M |
| Shares Outstanding | 131.02M |
| Shares Change (YoY) | +32.05% |
| Shares Change (QoQ) | -0.03% |
| Owned by Insiders (%) | 20.33% |
| Owned by Institutions (%) | 37.66% |
| Float | 62.86M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 141.62 |
| Forward PS | n/a |
| PB Ratio | 5.19 |
| P/TBV Ratio | 5.33 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 142.19 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.78, with a Debt / Equity ratio of 1.13.
| Current Ratio | 4.78 |
| Quick Ratio | 4.21 |
| Debt / Equity | 1.13 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -115.21% and return on invested capital (ROIC) is -50.06%.
| Return on Equity (ROE) | -115.21% |
| Return on Assets (ROA) | -40.36% |
| Return on Invested Capital (ROIC) | -50.06% |
| Return on Capital Employed (ROCE) | -70.27% |
| Revenue Per Employee | $17,972 |
| Profits Per Employee | -$943,977 |
| Employee Count | 214 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -134,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -24.87% in the last 52 weeks. The beta is 2.34, so Prime Medicine's price volatility has been higher than the market average.
| Beta (5Y) | 2.34 |
| 52-Week Price Change | -24.87% |
| 50-Day Moving Average | 2.45 |
| 200-Day Moving Average | 2.66 |
| Relative Strength Index (RSI) | 63.21 |
| Average Volume (20 Days) | 5,811,509 |
Short Selling Information
The latest short interest is 20.14 million, so 15.38% of the outstanding shares have been sold short.
| Short Interest | 20.14M |
| Short Previous Month | 18.48M |
| Short % of Shares Out | 15.38% |
| Short % of Float | 32.05% |
| Short Ratio (days to cover) | 6.58 |
Income Statement
In the last 12 months, Prime Medicine had revenue of $3.85 million and -$202.01 million in losses. Loss per share was -$1.61.
| Revenue | 3.85M |
| Gross Profit | -151.57M |
| Operating Income | -206.52M |
| Pretax Income | -217.55M |
| Net Income | -202.01M |
| EBITDA | -200.01M |
| EBIT | -206.52M |
| Loss Per Share | -$1.61 |
Full Income StatementBalance Sheet
The company has $144.26 million in cash and $121.15 million in debt, giving a net cash position of $23.11 million or $0.18 per share.
| Cash & Cash Equivalents | 144.26M |
| Total Debt | 121.15M |
| Net Cash | 23.11M |
| Net Cash Per Share | $0.18 |
| Equity (Book Value) | 106.92M |
| Book Value Per Share | 0.84 |
| Working Capital | 129.48M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$104.02 million and capital expenditures -$7.39 million, giving a free cash flow of -$111.41 million.
| Operating Cash Flow | -104.02M |
| Capital Expenditures | -7.39M |
| Free Cash Flow | -111.41M |
| FCF Per Share | -$0.85 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -5,369.68% |
| Pretax Margin | -5,255.98% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Prime Medicine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -32.05% |
| Shareholder Yield | -32.05% |
| Earnings Yield | -35.44% |
| FCF Yield | -19.55% |
Analyst Forecast
The average price target for Prime Medicine is $9.38, which is 115.63% higher than the current price. The consensus rating is "Buy".
| Price Target | $9.38 |
| Price Target Difference | 115.63% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 58.79% |
| EPS Growth Forecast (5Y) | -13.30% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Prime Medicine has an Altman Z-Score of -3.38 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.38 |
| Piotroski F-Score | 3 |
